Leerink Partners maintains Medline at Outperform, raises price target to $46 from $43

Leerink Partners kept Medline at Outperform, raising its price target to $46 from $43, suggesting 14% upside from the Nov 4 close. Recent analyst targets range from $43 to $55.

Original reporting
Published Nov 5, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Medline at Outperform, raises price target to $46 from $43 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target increase reflects a modest bullish view but does not constitute a material catalyst for the broader market.

02

Market read

A small analyst rating change with limited trading relevance.

03

What to watch

Medline remains privately held, limiting liquidity and broader market impact.

Relevance 5/10Novelty 5/10Timing: today

Background

Analyst Leerink Partners upgraded Medline's price target from $43 to $46, implying a 14% upside from the recent close.

Market effects

Minimal impact on medical supplies sector as the change is a modest analyst target adjustment.

No regional effect.

Limited to investors tracking Medline analyst coverage.

Counterpoint

The target raise may be overly optimistic given limited growth catalysts.

Key entities

  • Medline

    Medical supplies manufacturer, privately held.

  • Leerink Partners

    Equity research firm providing the rating upgrade.

Related articles

$MDLNMed

Medline stock falls as shareholders price secondary offering

Medline Inc (MDLN) shares fell 3.5% premarket after selling stockholders, including affiliates of Blackstone and Carlyle, priced a 60M share secondary offering at $35.50 per share. Medline will repurchase $200M of stock from these sellers. The offering is expected to close November 23, 2026, with underwriters having a 30-day option for additional shares. Medline is not selling shares and will not receive proceeds.

$MDLNHighAI 9/10

Why is Medline stock sliding today?

Medline (MDLN) stock fell 3.3% in pre-market trading after a consortium of shareholders priced a secondary offering of 60 million shares at $35.50 each, totaling $2.13 billion. The offering's below-market price and a securities fraud investigation by Bleichmar Fonti & Auld LLP contributed to the decline. Medline is not selling shares and will not receive proceeds. The stock has dropped significantly from its 52-week high of $50.88.